Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

VRN110755

PreclinicalSmall molecule

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

EGFR-Mutant Non-Small Cell Lung CancerRecruiting

EGFR-Mutant Non-Small Cell Lung CancerPreclinical

Recruiting

Timeline

Expected Milestones

Q1 2029

PreclinicalRecruiting

EGFR-Mutant Non-Small Cell Lung Cancer

NCT07699328

Clinical

Trials by Indication[1]

Tics1 trial

A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755

Recruiting·VVoronoi, Inc·Phase 1·NCT07141381·24 enrolled

EGFR-mutant Non-small Cell Lung Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Recruiting·VVoronoi, Inc·Preclinical·NCT07699328·315 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VRN110755. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VRN110755 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VRN110755. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Voronoi, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VVoronoi, Inc

Related News